All News
RheumNow’s expanded coverage of #ACR23 annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty.
Dr. John Cush RheumNow ( View Tweet)
Long term follow up T2T in RA
12 yrs BeST & 20yrs IMPROVED studies
50% recalled
68% remission 91% LDA
HAQ 0.5
These are GOOD outcomes
Especially considering setup before we had several MoAs
What’s lacking: current ttmt & number of bioD, ctrl group
@RheumNow ABST1273 #ACR23 https://t.co/9KcsHLupJc
Aurelie Najm ( View Tweet)
#ACR23 Abstr#1579 More data on the role of SGLT2-i in #SLE. Data from EHR using propensity match scoring showed the use of SGLT2-i vs DPP4-i (for nonSLE indication) was associated with reduced risk of MACE (HR:0.69)and poor renal outcomes inc. ESRD (HR:0.71) @RheumNow https://t.co/7k0o3m18AN
Md Yuzaiful Md Yusof ( View Tweet)
Does NSAID use = CKD?
Large Korean study on CKD in ankylosing spondylitis pts showed risk of CKD associated with comorbidities.
Long term NSAID use not associated with increased risk of CKD.
@RheumNow #ACR23 Abs#1394 https://t.co/m3kYI30gBc
Robert B Chao, MD ( View Tweet)
OA and Microbiome!
Ab#1581 @RheumNow #ACR23
Microbiome transplantation of mouse models - benefit if before or soon after OA induction (meniscal destabilization)
⭐️OA is inflammatory dis of innate immune sys, not "wear-and-tear" and gut biome may be a 🔑 https://t.co/eA8unUBnpC
Eric Dein ( View Tweet)
Risk of CKD in AS patients was associated with comorbidities, not NSAID use. #ACR23 Abs #1394 https://t.co/cbOPvjOCyq @rheumnow https://t.co/O0rhbMFiOX
Dr. Rachel Tate ( View Tweet)
Majority of pts with axSpA had below avg aerobic capacity indicating high risk of morbidity.
Importance of supporting pts with axSpA to lead healthy lifestyle and improved aerobic capacity by exercise!
@RheumNow #ACR23 Abs#1395 https://t.co/SFAStGQaK0
Robert B Chao, MD ( View Tweet)
Apremilast associated with improvement in LDL, obesity and diabetic A1c in PsA pts, especially in those with worse levels at baseline!
Can consider apremilast use in PsA with high burden of comorbid cardiometabolic diseases
@RheumNow #ACR23 Abs#1414 https://t.co/fL9UWcaZgG
Robert B Chao, MD ( View Tweet)
RA-ILD is an heterogeneous condition
Different risk factors identified dep/ on radiographic pattern
RA-UIP:
-male sex OR 2.7
-ACPA+ OR 2.2
-male + ACPA + smoking OR 13
RA-NSIP:
-RF+ OR 3.2
Likely to support different pathological mechanisms
@RheumNow #ACR23 ABST1269 https://t.co/rC2F9YAceQ
Aurelie Najm ( View Tweet)
Can US differentiate pain? In #ACR23 Abs. #1388 PsA pts who have pain & inflammatory enthesitis on US, process pain differently than the US negative patients, despite the induction of pain or discomfort on all groups. Interesting finding. https://t.co/YcccLoQCBj @rheumnow https://t.co/o94bMwndxX
Dr. Rachel Tate ( View Tweet)
Finally meeting @synovialjoints after 3 years of reporting together for @RheumNow!
Some serious interviews on AxSPA going on at the booth, I won’t reveal who was his guest: you’ll have to find out on https://t.co/YxAt6H2Qza https://t.co/dQHPw3pS3d
Aurelie Najm ( View Tweet)
What if you have a first degree relative with ankylosing spondylitis?
100 pts w/o previous rheum dx w/ 1st degree AS relative
17% had MRI sacroiliitis
25% met classification criteria
14% dx with AS
@RheumNow #ACR23 Abs#1403 https://t.co/Z0juhRnLki
Robert B Chao, MD ( View Tweet)
15-year results from Abs #1389 at #ACR23 found only low back pain to be predictor of spinal radiographic progression in axSpA pts. Mean and median progression changes by mSASSS per year less in this cohort than previously documented. https://t.co/VKTEZWvH7f @rheumnow https://t.co/6sjPrcw2dD
Dr. Rachel Tate ( View Tweet)
Biologics are working for ankylosing spondylitis, even in reducing cardiovascular mortality!
Large retrospective study of over 4k pts over 20 years showed decrease in CV mortality from 34% in 1999 to 21% in 2020
@RheumNow #ACR23 Abs#1399
#ACRbest https://t.co/wKCIXHza0v
Robert B Chao, MD ( View Tweet)
Although general agreement that dz activity monitoring is important, implementation of AS/axSpA guideline recommendations is lacking. Guideline uptake & implementation should be considered in future updates of axSpA/AS tx recs. #ACR23 Abs #1385 https://t.co/RsyDppe3aR @rheumnow https://t.co/xxZ9pa77h9
Dr. Rachel Tate ( View Tweet)
Defining accuracy of Administrative Codes for Autoinflammatory Syndromes is important to lay groundwork!
AOSD, SJIA, BD, FMF, CAPS and SAPHO-CNO ICD codes validated as Autoinflammatory syndromes (AIS)- PPV low
@RheumNow #ACR23 #abst1129 https://t.co/XqIrUmUCVc
Bella Mehta bella_mehta ( View Tweet)
Never forget the physical toll that RA has taken on our patients.
RA pts in BC🇨🇦, dx 1996-2008 (n=13367)
Fraility score 5y post-dx:
twice as likely to be frail vs matched controls
I would love to see those dx 2008-2018
Have biologics moved the needle?
#ACR23 ABST1275 @RheumNow https://t.co/gMXo5Pp1qA
David Liew drdavidliew ( View Tweet)
Upcoming Plenary II session
Ab#1584 on Bactrim for GPA pts on RTX
Should you use this for prophylaxis after weaning the prednisone?
#ACR23 @RheumNow
Eric Dein ( View Tweet)
#ACR23 Abstr#0509 Is sero-ve #Sjogren sero-ve? A study showed promising diagnostic model comprises clinical & novel autoantibodies (DTD2) using whole peptidome array (AUC:74%) to avoid need for lips biopsy in ANA-ve. Need further validation & wider access to this test @RheumNow https://t.co/FmE8AJdMVe
Md Yuzaiful Md Yusof ( View Tweet)
In this updated pooled safety analysis from clinical trials of PsO, PsA & axSpA pts given SEC 150 &/or 300mg SC (ADeodhar et al)
⬆️freq AEs: nasopharyngitis & URTI
Low EAIRs/100pt yrs for IBD, malignancies & MACE
No new safety signals
Reassuring data.
#ACR23 ABST1436 @RheumNow https://t.co/guF0gC4hQM
sheila ( View Tweet)